mast therapeutics inc (MSTX:NYSE Amex)

Executive Profile*

Background*

Dr. Edward Chu, M.D. serves as the Chief of the Division of Hematology/Oncology in the Department of Medicine at the University of Pittsburgh School of Medicine. Dr. Chu serves as Deputy Director of the University of Pittsburgh Cancer Institute (UPCI) and is Co-leader of the UPCI Molecular Therapeutics and Drug Discovery Program. In this role, he is involved in basic, clinical and translational cancer research. Dr. Chu served as a Professor of Medicine and Pharmacology ... at the Yale University School of Medicine. He served as deputy director of the Yale Cancer Center and Yale School of Medicine. He served as the Chief of Medical Oncology at Yale University. Dr. Chu serves as co-Director of the Developmental Therapeutics Program at the Yale Cancer Center. After his residency, he joined the National Cancer Institute (NCI) in Bethesda, Maryland for a fellowship in medical oncology. Following completion of his fellowship, he remained at the NCI as a Senior Clinical Investigator. In 1996, he was recruited to the Yale Cancer Center of the Yale University School of Medicine, where he assumed the position of Director of the VA CT Cancer Center and Associate Director of the Yale Cancer Center. Dr. Chu has been Chairman of Scientific Advisory Board at Saladax Biomedical, Inc. since November 2011. Dr. Chu serves as a Member of the Scientific Advisory Board at Adventrx Pharmaceuticals Inc. and Celator Pharmaceuticals, Inc. He serves as a Director of YM BioSciences USA Inc. (also known as EXIMIAS Pharmaceutical Corporation). Dr. Chu is also the editor-in-chief for "Clinical Colorectal Cancer," a member of the scientific advisory boards of the Taiwan National Institute of Cancer Research, Albert Einstein Cancer Center and the Dartmouth Norris Cancer Center. He has authored numerous articles and oncology book chapters and is well respected in the oncology community for his work. Dr. Chu received his M.D. from Brown University, where he also completed his residency training in internal medicine.

Report Data Issue

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Recently Viewed
MSTX:US	$0.66 USD	-0.007

COMPETITOR COMPENSATION